Key takeaways for South Carolina
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • Healthy Connections coverage rules apply for Insulin Resistance patients in South Carolina — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
South Carolina-specific context
South Carolina has telehealth access concentrated in Charleston, Columbia, North Charleston metros, with additional reach to Mount Pleasant and Greenville. MUSC Health, Prisma Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at scdhec.gov.
South Carolinatelehealth & pricing rules
- • South Carolina permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • South Carolina allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in South Carolina: ~$229/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.